Skip to main content
Clinical Trials/JPRN-UMIN000001146
JPRN-UMIN000001146
Completed
Phase 2

Phase II study with tacrolimus to prevent GVHD for reduced-intensity peripheral blood stem cell transplantation from an HLA-identical related donor - Phase II study with tacrolimus to prevent GVHD for reduced-intensity PBSCT from an HLA-identical related donor

agoya Blood and Marrow Transplantation Group0 sites26 target enrollmentStarted: June 1, 2008Last updated:

Overview

Phase
Phase 2
Status
Completed
Sponsor
agoya Blood and Marrow Transplantation Group
Enrollment
26

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
16years-old to 65years-old (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • (1\)Positive for HIV antibody andor HBs antigen (2\)T cell depleted transplantation (3\)Pregnant or during breast feeding (4\)Uncontrolled psychiatric disease (5\)Uncontrolled active infection (6\)Allergic history to drugs used in the present conditioning regimen or GVHD prophylaxis regimen (7\)A history of intravenous chemotherapy within 21 days before transplantation (8\)Cases that physicians judged as inappropriate

Investigators

Sponsor
agoya Blood and Marrow Transplantation Group

Similar Trials

Completed
Not Applicable
Tacrolimus (graceptor (R)) for GVHD prophylaxis after allogeneic stem cell transplantatioacute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, myelodysplastic syndrome, malignant lymphoma
JPRN-UMIN000002441Jikei university school of medicine10
Terminated
Phase 2
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant PatientsAcute LeukemiaChronic Lymphocytic LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveDiffuse Large B-Cell LymphomaFollicular LymphomaGraft Versus Host DiseaseMantle Cell LymphomaMarginal Zone LymphomaMyelodysplastic SyndromeMyelofibrosisMyeloproliferative NeoplasmSmall Lymphocytic Lymphoma
NCT02877082Emory University5
Completed
Phase 3
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD PreventionChronic Myelogenous LeukemiaAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Biphenotypic LeukemiaMyelodysplastic SyndromeMyeloproliferative NeoplasmNon-Hodgkin LymphomaHodgkins DiseaseChronic Lymphocytic LeukemiaMultiple Myeloma
NCT01951885Case Comprehensive Cancer Center101
Completed
Phase 1
PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC TransplantationAcute LeukemiaMyelodysplastic SyndromesMyeloproliferative NeoplasmLymphoma
NCT05120570Masonic Cancer Center, University of Minnesota75
Completed
Phase 2
Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) PreventionGraft Versus Host DiseaseGVHD
NCT02588339H. Lee Moffitt Cancer Center and Research Institute42